Adriana Rossi, MD
Disclosures
Rossi reports consulting for Bristol-Myers Squibb, Caribou Biosciences, Janssen Pharmaceuticals, Karyopharm and Sanofi-Aventis.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Much of what we are doing is how to enhance the things that we've already gotten. You know, I think with the advent of cilta-cel having a nearly hundred percent response rate being used in, you know, first, very relapsed and then moving earlier lines, it really has set the bar very high, as we've seen about a third of patients in the four lines or plus multiply relapse being able to be off therapy for years, with no relapse and no further treatment. I think the bar is high, but I'm excited to see some of these novel areas, such as the new manufacturing of T1-cells, maybe combinations of bispecifics, and maybe combining these different modalities, you know, in a sequential manner to really start using the word cure in myeloma.
